ONTX News and Press, Onconova Therapeutics Inc. From 11/11/22

Onconova Therapeutics ( NASDAQ: ONTX ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $0.07M (+16.7% Y/Y). Over the last 1 year, ONTX has beaten EPS...

NEWTOWN, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to relea...

NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be partici...

Onconova Therapeutics ( NASDAQ: ONTX ) said updated data from a phase 1/2a trial of oral rigosertib and Bristol-Myers Squibb's ( NYSE: BMY ) Opdivo (nivolumab) showed early signs of efficacy in  certain extensively pre-treated patients with non-small c...

Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patients Responses achieved in patients with 3 distinct and different KRAS mutations, confirming the MOA of rigosertib bei...

NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be partici...

2Q22 Onconova Reported Trial Progress. 2Q22 loss of $4.0 million or $(0.19) per share, compared with our estimated loss of $3.7 million or $(0.18) per share. Several clinical trials for both narazaciclib and rigosertib are continuing as expected. The company ended the quarter with $46.5 millio...

Onconova Therapeutics, Inc. (ONTX) Q2 2022 Earnings Conference Call August 11, 2022 16:30 ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Steve Fruchtman - President & Chief Executive Officer Mark Gelder - Chief Medical Officer ...

Onconova Therapeutics press release ( NASDAQ: ONTX ): Q2 GAAP EPS of -$0.19 beats by $0.01 . Revenue of $0.06M in-line (flat Y/Y). Cash and cash equivalents as of June 30, 2022, were $46.5M, compared with $55.1M as of December 31, 2021. The company believes tha...

NEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three m...